Commercial
The field force: Is small beautiful?
As big pharma ponders the right sizing of its post-pandemic field forces, can it learn from smaller, leaner industry peers about doing more with less?
Clinical
Synthetic data: pharma’s next big thing?
Get ready for a new data technology to begin its journey through the hype cycle: synthetic data. Synthetic data will account for...
Commercial
Cell & Gene Therapy: High stakes and high hopes for healthcare
Revolutionary cell and gene therapies (CGT) delivering breakthrough treatments have begun to disrupt healthcare. The companies building...
Latest
-
-
Access and Evidence
How automation is changing regulatory affairs
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing -
Multichannel
Modularise to personalise
Digital-first engagement is challenging pharma to deliver content on HCPs’ terms and a modular approach is key -
Commercial
Cell & Gene Therapy: High stakes and high hopes for healthcare
Now that CGT is proving its worth, the next task for pharma is working out the best ways to commercialise it -
Clinical
Synthetic data: pharma’s next big thing?
Faster, better trials, enhanced pharmacoepidemiology and more ambitious cross-border research are just some of the likely use cases for synthetic data
Most Popular
Andrew Stone, (Apr 1, 2022)
Digital-first engagement is challenging pharma to deliver content on HCPs’ terms and a modular approach is key
Pamela Whitby, (Mar 29, 2022)
Now that CGT is proving its worth, the next task for pharma is working out the best ways to commercialise it
Andrew Stone, (Apr 14, 2022)
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing
Opinion
Jill Donahue, (Feb 13, 2022)
Paying it forward and helping others act on their patient-driven purpose is the goal of this pharma leader
Jill Donahue, (Jun 7, 2021)
Following in his physician father's footsteps, for this pharma leader it's always been about the patient
Commercial
-
The field force: Is small beautiful?
As big pharma ponders the right sizing of its post-pandemic field forces, can it learn from smaller, leaner industry peers about doing more with less? -
Cell & Gene Therapy: High stakes and high hopes for healthcare
Now that CGT is proving its worth, the next task for pharma is working out the best ways to commercialise it -
Unlocking the full potential of biosimilars
The future looks bright for biosimilars in an age of crisis over healthcare affordability -
Accelerating commercial success in CAGT
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in -
Blended and augmented: Reimagining the role of the rep
The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement
Access and Evidence
-
How automation is changing regulatory affairs
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing -
An early peek at the FDA’s RWE ‘cookbook’
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know -
The future is bright for RWE in pharma approvals
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task -
Payers and the ABCs of digital literacy
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other stakeholders understand how to use them -
Decoding the patient journey with RWD
Patient real-world data contains a wealth of potentially valuable information for life sciences commercial teams, if they can filter out the noise
Patients and Medical
-
Digital patient engagement data: Are you already falling behind?
Gathering and acting on insights from digital patient engagement data is becoming a competitive differentiator, yet many in pharma are still stuck in learning mode -
Reaching Gen-Z
Young people comprise a unique demographic that pharma is not used to serving but new digital tools offer ways to understand, engage and serve them better -
Helping patients help themselves
Self care offers a new way for health care companies to serve patients better globally and industry collaboration will drive faster progress -
Chiesi: Putting purpose at its heart
Italian pharma company Chiesi has embedded environmental and social purpose into its very corporate fabric -
Medical Affairs & Social Media: A Brave New World
A great majority of healthcare providers now use social media platforms. Medical Affairs teams need to amplify their voice on social media channels – or lose out.
Latest Videos
Upcoming Events
View All EventsJune 2022
-
FREE WEBINAR: Your 24-month blueprint for launch success
Jun 1, 2022 - Jun 1, 2022
September 2022
-
Cell & Gene Therapy USA 2022
Sep 20, 2022 - Sep 21, 2022
October 2022
-
Total Health USA 2022
Oct 4, 2022 - Oct 5, 2022
November 2022
-
Pharma Awards Europe 2022
Nov 17, 2022 - Nov 17, 2022